Lori A HazlehurstÂ
Professor (SOP)/Co-Leader
Pharmaceutical Sciences
West Virginia University
United States of America
Biography
Dr. Hazlehurst earned her Ph.D. from the Cell and Molecular Biology Program at the University of Vermont. Her post-doctoral studies were performed at the University of Arizona and the Moffitt Cancer Center. Her studies focused on developing strategies for targeting the tumor microenvironment to increase the efficacy of standard of care agents. Her current research focus is to develop strategies for targeting Ca2+ homeostasis in cancer. The laboratory focus is translational with an overall goal of developing novel therapeutic strategies for the treatment of cancer.
Research Interest
Hematopoietic Malignancy and Transplantation
Publications
-
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular cancer therapeutics. 2013 Nov 1;12(11):2446-58.
-
Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer research. 2014 Jan 1;74(1):56-67.
-
Shay G, Hazlehurst L, Lynch CC. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of Molecular Medicine. 2016 Jan 1;94(1):21-35.
